Folate receptor alpha vaccine(Mayo Clinic)(Folate receptor alpha vaccine(Mayo Clinic)) - 药物靶点：FOLR1_在研适应症：卵巢子宫内膜样癌，输卵管透明细胞腺癌，高级别输卵管浆液性腺癌_专利_临床

概要

基本信息

药物类型

治疗性疫苗、树突状细胞疫苗

别名

FR alpha peptide vaccine、FRa peptide vaccine、FRalphaDC

+ [6]

靶点

FOLR1

作用方式

调节剂

作用机制

FOLR1调节剂(叶酸受体α调节剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [2]

在研适应症

卵巢子宫内膜样癌输卵管透明细胞腺癌高级别输卵管浆液性腺癌+ [6]

非在研适应症

3型乳腺癌复发性乳腺癌铂耐药性卵巢癌+ [4]

原研机构

Mayo Clinic

在研机构

Mayo Clinic

非在研机构

Marker Therapeutics, Inc.

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 1646436

Sequence Code 9957632

Sequence Code 9957689

Sequence Code 9957680

Sequence Code 9957659

关联

5

项与 Folate receptor alpha vaccine(Mayo Clinic) 相关的临床试验

NCT06639074

/ Recruiting临床2期IIT

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients with Advanced Stage Ovarian Cancer: a Phase II Double-Blind Randomized Clinical Trial (FAROUT)

This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopian tube or primary peritoneal cancer. FRαDCs, a dendritic cell vaccine, is made from a person's white blood cells. The white blood cells are treated in the laboratory to make dendritic cells (a type of immune cell) mixed with folate receptor alpha (FRalpha), a protein found in high levels on ovarian tumor cells. FRαDCs work by boosting the immune system to recognize and destroy the tumor cells by targeting the FRalpha protein on the tumor cell. Placebo is an inactive substance that looks the same as, and is given the same way as, the active drug or treatment being tested. The effects of the active drug are compared to the effects of the placebo. Giving FRαDCs may work better in preventing or delaying recurrence compared to placebo in patients with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.

开始日期2024-11-08

申办/合作机构

Mayo Clinic

NCT02978222

/ Terminated临床2期

A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy

This is a double-blind, randomized, parallel groups Phase II trial. Patients with platinum-sensitive advanced ovarian cancer, defined as a lack of progression by RECIST v1.1 criteria following completion of standard-of-care chemotherapy, including a minimum of 4 cycles of a platinum-containing regimen. Patients will be randomized to either the vaccine regimen with GM-CSF adjuvant or GM-CSF adjuvant alone as a control group. Treatment will be administered as a consolidation therapy within one year of the last administration of platinum, targeting the first remission.

开始日期2017-07-20

申办/合作机构

Marker Therapeutics, Inc.

NCT02764333

/ Completed临床2期IIT

A Phase II Trial of TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

This is a Phase 2 clinical trial, which tests two investigational drugs: TPIV200/huFR-1 (also called TPIV200), which is a vaccine consisting of proteins from the folate receptor alpha mixed with GM-CSF, and durvalumab (MEDI4736) , which is an antibody drug that help un-block parts of the immune system. The aim of this study is to find out whether these drugs, when given together are safe, and whether they are effective in treating cancer.

开始日期2016-05-06

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+2]

100 项与 Folate receptor alpha vaccine(Mayo Clinic) 相关的临床结果

登录后查看更多信息

100 项与 Folate receptor alpha vaccine(Mayo Clinic) 相关的转化医学

登录后查看更多信息

100 项与 Folate receptor alpha vaccine(Mayo Clinic) 相关的专利（医药）

登录后查看更多信息

2

项与 Folate receptor alpha vaccine(Mayo Clinic) 相关的文献（医药）

2024-10-01·Gynecologic Oncology

Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial

Article

作者: Block, Matthew S ; Potts, James ; Knutson, Keith L ; Kenney, Richard T ; O'Cearbhaill, Roisin E ; Hamilton, Erika ; Garrett, Gerald ; Konner, Jason A ; Gupta, Aditi ; Wenham, Robert M

OBJECTIVEFolate receptor alpha (FRα) is overexpressed on >90% of high-grade epithelial ovarian cancers (EOC). Targeting FRα with antibody-drug conjugates has proven utility in the platinum-resistant setting. It is also a potential therapeutic target for immuno-oncologic agents, such as peptide vaccines that work primarily via adaptive and humoral immunity. We tested the hypothesis that FRα peptide immunization could improve outcomes in patients with EOC following response to platinum-based therapy.METHODSWe conducted a randomized, double-blind, multicenter, phase II study to evaluate the safety and efficacy of TPIV200 (a multi-epitope FRα peptide vaccine admixed with GM-CSF) versus GM-CSF alone in 120 women who did not have disease progression after at least 4 cycles of first-line platinum-based therapy. Patients were vaccinated intradermally once every 4 weeks up to 6 times, followed by a boosting period of 6 vaccinations at 12-week intervals. Primary endpoints included safety, tolerability, and progression free survival (PFS).RESULTSAt study termination with a median follow-up of 15.2 months (range 1.2-28.4 months), 68 of 119 intention-to-treat patients had disease progression (55% in TPIV200 + GM-CSF arm and 59% in GM-CSF alone arm). The median PFS was 11.1 months (95% CI 8.3-16.6 months) with no significant difference between the treatment groups (10.9 months with TPIV200 + GM-CSF versus 11.1 months with GM-CSF, HR, 0.85; upper 90% CI 1.17]. No patient experienced a ≥ grade 3 drug-related adverse event.CONCLUSIONTPIV200 was well tolerated but was not associated with improved PFS. Additional studies are required to uncover potential synergies using multiepitope vaccines targeting FRα. Trial Registration NLM/NCBI Registry, NCT02978222, https://clinicaltrials.gov/search?term=NCT02978222.

2020-06-01·Journal for ImmunoTherapy of Cancer2区 · 医学

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

2区 · 医学

ArticleOA

作者: Mcdonnell, Autumn S ; Chesebrough, Lewis F ; Knutson, Keith L ; Zamarin, Dmitriy ; Hollmann, Travis J ; Block, Mathew S ; Torrisi, Jean M ; Aghajanian, Carol ; Gallagher, Jacqueline M ; Zhou, Qin ; Grisham, Rachel N ; Merghoub, Taha ; Iasonos, Alexia E ; Konner, Jason A ; Erskine, Courtney L ; O'Cearbhaill, Roisin E ; Holland, Aliya ; Walderich, Sven ; Li, Yanyun

BackgroundImmune checkpoint inhibitors (ICIs) to date have demonstrated limited activity in advanced ovarian cancer (OC). Folate receptor alpha (FRα) is overexpressed in the majority of OCs and presents an attractive target for a combination immunotherapy to potentially overcome resistance to ICI in OCs. The current study sought to examine clinical and immunologic responses to TPIV200, a multiepitope FRα vaccine administered with programmed death ligand 1 (PD-L1) inhibitor durvalumab in patients with advanced platinum-resistant OC.MethodsFollowing Simon two-stage phase II trial design, 27 patients were enrolled. Treatment was administered in 28-day cycles (intradermal TPIV200 and granulocyte-macrophage colony-stimulating factor (GM-CSF) for 6 cycles and intravenous durvalumab for 12 cycles). Primary endpoints included overall response rate and progression-free survival at 24 weeks. Translational parameters focused on tumor microenvironment, PD-L1 and FRα expression, and peripheral vaccine-specific immune responses.ResultsTreatment was well tolerated, with related grade 3 toxicity rate of 18.5%. Increased T cell responses to the majority of peptides were observed in all patients at 6 weeks (p<0.0001). There was one unconfirmed partial response (3.7%) and nine patients had stable disease (33.3%). Clinical benefit was not associated with baseline FRα or PD-L1 expression. One patient with prolonged clinical benefit demonstrated loss of FRα expression and upregulation of PD-L1 in a progressing lesion. Despite the low overall response rate, the median overall survival was 21 months (13.5–∞), with evidence of benefit from postimmunotherapy regimens.ConclusionsCombination of TPIV200 and durvalumab was safe and elicited robust FRα-specific T cell responses in all patients. Unexpectedly durable survival in this heavily pretreated population highlights the need to investigate the impact of FRα vaccination on the OC biology post-treatment.

1

项与 Folate receptor alpha vaccine(Mayo Clinic) 相关的新闻（医药）

2018-08-29

·BioSpace

TapImmune to Participate at Two Upcoming September 2018 Industry Conferences

JACKSONVILLE, Fla., Aug. 29, 2018 /PRNewswire/ -- TapImmune Inc.(NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming industry conferences. Mr. Hoang will present and participate in a panel discussion at the Hanson Wade CAR-TCR Summit, to be held September 4-7, 2018, in Boston, Massachusetts, and present at BioCentury's 25th Annual NewsMakers in the Biotech Industry to be held September 7, 2018, in New York City. CAR-TCR Summit Details: Date: Wednesday, September 5, 2018 Location: Cityview Room; Seaport Hotel and World Trade Center, Boston, MA Time: 2:25pm (ET): Company Presentation 5:15pm (ET): Panel - How to Make CAR/TCR Therapies Work Beyond the CD19/ALL Paradigm BioCentury Newsmakers Presentation Details: Date: Friday, September 7, 2018 Location: Millennium Broadway Hotel & Conference Center, New York City, NY Time: 2:30pm (ET): Presentation - Room 302/303 3:00pm (ET): Breakout Session - Room 301 Webcast: Available at About TapImmune Inc. TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The Company's peptide or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) that are designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T cell vaccine candidates that elicit a broad-based T cell response and can be used without respect to HLA type. The Company's technologies may be used as stand-alone medications or in combination with other treatment modalities. TapImmune has announced a proposed merger with Marker Therapeutics, Inc., a privately-held clinical stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform, which will add a significant portfolio of clinical-stage cell therapies to create a leading immuno-oncology pipeline. For additional information, please visit: To receive future press releases via email, please visit: Follow us on Twitter @Tapimmune_Inc, or follow us on Facebook. For answers to frequently asked questions, please visit our FAQs page: Forward-Looking Statement Disclaimer This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase 2 clinical trials, the ability to obtain regulatory approval of TPIV200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize TPIV200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at The Company assumes no obligation to update the forward-looking statements. View original content with multimedia: SOURCE TapImmune Inc. Company Codes: NASDAQ-SMALL:TPIV

细胞疗法疫苗并购

100 项与 Folate receptor alpha vaccine(Mayo Clinic) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
卵巢子宫内膜样癌	临床2期	美国	Mayo Clinic	2024-11-08
输卵管透明细胞腺癌	临床2期	美国	Mayo Clinic	2024-11-08
卵巢高级别浆液性腺癌	临床2期	美国	Mayo Clinic	2024-11-08
卵巢腺癌	临床2期	美国	Mayo Clinic	2024-11-08
原发性腹膜透明细胞癌	临床2期	美国	Mayo Clinic	2024-11-08
原发性腹膜子宫内膜样腺癌	临床2期	美国	Mayo Clinic	2024-11-08
原发性腹膜高级别浆液性腺癌	临床2期	美国	Mayo Clinic	2024-11-08
铂敏感性卵巢癌	临床1期	美国	Marker Therapeutics, Inc.	2017-07-20
铂耐药性卵巢癌	临床1期	美国	Marker Therapeutics, Inc.	2016-05-06
三阴性乳腺癌	临床1期	美国	Marker Therapeutics, Inc.	2016-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02978222 (Pubmed) 人工标引	临床2期	卵巢癌	120	TPIV200receptor-alpha peptides (TPIV200 + GM-CSF)	(壓衊鑰襯膚鑰醖鏇艱衊) = 壓壓遞簾餘糧築積鹽壓鹹鹹鏇顧構餘糧鹽襯襯 (構鹹襯製獵淵網衊鏇鹹 )	不佳	2024-10-01
NCT02978222 (Pubmed) 人工标引	临床2期	卵巢癌	120	GM-CSF alone	(壓衊鑰襯膚鑰醖鏇艱衊) = 選醖願衊齋鑰鑰鏇齋齋鹹鹹鏇顧構餘糧鹽襯襯 (構鹹襯製獵淵網衊鏇鹹 )	不佳	2024-10-01
NCT02978222 (NCT02978222 \| ###DELETE, CTgov)	临床2期	铂敏感性卵巢癌	120	FRα peptide plus Adjuvant (GM-CSF) (FRα Peptide Plus Adjuvant (GM-CSF))	(壓遞鬱淵選遞繭夢襯鬱) = 夢製網顧憲鹹繭淵艱範襯糧艱顧鬱齋鬱構糧簾 (衊簾鏇鑰製壓築膚獵鏇, 鏇願憲選積夢遞艱繭壓 ~ 壓淵鬱積壓鬱獵範觸膚) 更多	-	2022-12-15
NCT02978222 (NCT02978222 \| ###DELETE, CTgov)	临床2期	铂敏感性卵巢癌	120	Adjuvant (GM-CSF) Alone (Adjuvant (GM-CSF) Alone)	(壓遞鬱淵選遞繭夢襯鬱) = 簾鑰觸繭積遞餘糧顧夢襯糧艱顧鬱齋鬱構糧簾 (衊簾鏇鑰製壓築膚獵鏇, 窪襯餘顧窪襯網築艱遞 ~ 蓋憲襯鹽蓋繭構餘築簾) 更多	-	2022-12-15
NCT02764333 (CTgov)	临床2期	铂耐药性卵巢癌	29	TPIV200+Durvalumab	簾醖夢憲憲憲膚築範蓋(鹹遞壓襯鑰鏇繭構鹹壓) = 鹹積簾構壓願艱衊艱襯膚繭繭鑰餘廠鑰觸遞膚 (窪構構鏇積淵繭蓋壓醖, 觸製齋遞襯衊顧顧構範 ~ 衊製鑰衊憲膚選鬱憲窪) 更多	-	2021-11-30
NCT02764333 (Pubmed \| J Immunother Cancer) 人工标引	临床2期	卵巢癌	27	durvalumab+TPIV200	(選範獵積鑰醖艱簾蓋簾) = 顧蓋淵衊觸醖壓糧鏇餘顧願積夢壓網製鬱糧壓 (願糧選鏇蓋鹽壓獵遞鏇 ) 更多	积极	2020-06-01